查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401961

2030 年胰臟癌市場預測：按癌症類型、治療類型、診斷、癌症分期、受影響部位、最終用戶和地區進行的全球分析

Pancreatic Cancer Market Forecasts to 2030 - Global Analysis By Type, Treatment Type, Diagnosis, Stage of Cancer, Affected Area, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球胰臟癌市場規模為 29 億美元，預計預測期內複合年成長率為 15.6%，到 ​​2030 年將達到 81 億美元。

胰臟癌是一種影響胰臟的惡性，胰臟是位於胃後方的重要器官。當胰臟中的細胞不受控制地生長和分裂，形成腫瘤時，就會發生這種類型的癌症。它可以迅速轉移到附近的器官或身體的遠處部位，使治療變得困難。胰臟癌的症狀包括腹痛、體重減輕、黃疸、消化不良和疲倦。

根據美國癌症協會估計，到 2023 年，預計將有約 64,050 人被診斷出患有胰腺癌，約 50,550 人將死於胰腺癌。

胰臟癌發生率增加

癌症發病率正在迅速增加，原因包括不健康的用餐、缺乏運動、吸煙和飲酒、空氣污染和缺乏體力活動。由於癌症病例的特定年齡累積以及修復機制隨著年齡的成長而變得不那麼有效，癌症病例的發生率急劇增加。此外，被認為是癌症危險因子的慢性感染疾病正在增加，特別是在低收入和中等收入國家。因此，發病率上升是拉動市場需求的重要因素。

治療費用高

高治療成本是胰臟癌市場的主要威脅。胰臟癌的治療包括放射線治療、化療、手術和支持性治療，而且可能很昂貴。由於治療費用高昂，患者難以獲得治療，這可能會對獲得及時有效的治療產生負面影響。然而，治療的經濟負擔阻礙了患者接受必要的身體檢查和選擇建議的治療方法。這可能導致診斷延遲、治療方法選擇次優和治療結果不佳。

臨床研究增加

流行病學和基礎臨床研究的增加正在導致預防、診斷和治療方面的改善。研究人員繼續揭示胰臟癌背後複雜的分子和遺傳機制，為創新治療方法鋪路。此外，對新藥物研發標靶、生物標記和個人化醫療策略的探索證明胰臟癌研究正在不斷發展。因此，增加臨床研究是胰臟癌治療的機會。

副作用

胰臟癌治療在治療期間和治療後會產生各種副作用，這取決於患者。化療是最常見的癌症治療方法，其作用是殺死胰臟中的癌細胞，但它也會消除體內的健康細胞，這會對患者的健康產生負面影響，並導致副作用復發。此外，用於治療癌症的放射線治療具有皮膚發紅、噁心和食慾不振等副作用。在極少數情況下，輻射暴露甚至會導致腹瀉。因此，胰臟癌治療的副作用阻礙了市場的成長。

COVID-19 的影響

COVID-19大流行對胰臟癌市場產生了重大影響。這場大流行導致癌症篩檢、診斷和治療計劃以及其他常規衛生服務的延遲。由於限制、資源重新分配以及醫療保健重點轉向大流行管理，胰腺癌患者在獲得及時護理方面面臨障礙。此外，臨床試驗和研究活動也受到影響，減緩了新治療方法和治療方法的進展。

預計化療領域在預測期內將是最大的

化療部分估計佔最大佔有率。化療變得越來越流行，因為它具有阻止癌症擴散、殺死癌細胞、減緩疾病生長以及使用強力化學物質殺死快速生長的細胞等優點。它變得越來越普遍。此外，在胰臟癌的任何階段都使用化療來殺死癌細胞，並在診斷和恢復期間重複給藥藥物。此外，胰臟癌的化療可以在手術期間進行，也可以與放射線治療結合。

預計診所領域在預測期內的複合年成長率最高。

預計診所業務在預測期內將出現良好成長。專科診所和癌症中心發展的主要驅動力是真正的治療與優質服務的結合。由於腫瘤科醫生和醫療保健專業人員共用相同的身份和專業知識，因此臨床人員的可用性是專科診所的優勢，使患者能夠輕鬆且經濟地接受診斷和治療。專科診所僅提供專門的醫療服務，例如為癌症患者提供癌症中心，更容易管理保險和患者時間表，並利用癌症治療的最新進展。

佔有率最大的地區：

在估計期間，亞太地區佔據最大的市場佔有率。該地區人口眾多且正在迅速擴張，導致胰臟癌的高盛行率。吸煙、肥胖和糖尿病等危險因素的流行進一步增加了該地區的疾病負擔。此外，亞太地區癌症治療的可近性和衛生基礎設施的品質都在改善。包括影像和分子測試在內的先進診斷技術的出現，改善了胰臟癌的早期檢測和診斷。這改善了患者的治療效果並增加了該地區對診斷服務的需求。

複合年成長率最高的地區：

預計北美在預測期內將實現盈利成長。北美胰臟癌盛行率很高，是研究、診斷和治療進展的關鍵地區。該地區強大的研究基礎設施和資助機會在了解疾病和開發標靶治療方面取得了長足進展。此外，北美擁有完善的醫療保健系統，可以獲得專門的醫療服務和先進的治療選擇。

免費客製化服務：

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球胰臟癌市場：依類型

  • 介紹
  • 胰臟神經內分泌腫瘤
  • 胰臟腺癌

第6章全球胰臟癌市場：依治療類型

  • 介紹
  • 免疫療法
  • 外科手術
  • 化療
  • 荷爾蒙治療
  • 標靶藥物治療
  • 放射治療
  • 其他治療類型

第7章全球胰臟癌市場：依診斷分類

  • 介紹
  • 電腦斷層掃描 (CT) 掃描
  • 驗血
  • 正子斷層掃描 (PET) 掃描
  • 超音波
  • 磁振造影(MRI)
  • 切片檢查
  • 其他診斷

第8章全球胰臟癌市場：依癌症階段分類

  • 介紹
  • 階段
  • 局部進行性
  • 轉移性

第9章全球胰臟癌市場：依受影響地區

  • 介紹
  • 內分泌
  • 外分泌

第 10 章 全球胰臟癌市場：依最終用戶分類

  • 介紹
  • 醫院
  • 診斷實驗室
  • 研究
  • 其他最終用戶

第11章全球胰臟癌市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司簡介

  • Diffusion Pharmaceuticals
  • Novartis International AG
  • Amgen, Inc.
  • Pharmacyte Biotech Inc.
  • Polaris Pharmaceuticals, Inc.
  • Clovis Oncology
  • OncoGenex Pharmaceuticals Inc.
  • Oncolytics Biotech
  • Sun BioPharma, Inc.
  • Eli Lilly and Company
  • Midatech Pharma PLC
  • F. Hoffmann-La Roche AG
  • Celgene Corporation
Product Code: SMRC24481

According to Stratistics MRC, the Global Pancreatic Cancer Market is accounted for $2.9 billion in 2023 and is expected to reach $8.1 billion by 2030 growing at a CAGR of 15.6% during the forecast period. Pancreatic cancer is a malignant neoplasm affecting the pancreas, a crucial organ located behind the stomach. This type of cancer occurs when cells in the pancreas undergo uncontrolled growth and division, forming a tumor. It can spread rapidly to nearby organs and distant sites in the body, making it challenging to treat. Symptoms of pancreatic cancer may include abdominal pain, weight loss, jaundice, digestive problems, and fatigue.

According to o the America's Cancer Society for pancreatic cancer, about 64,050 people will be diagnosed with pancreatic cancer in 2023 and estimation of around 50,550 people will die of pancreatic cancer.

Market Dynamics:

Driver:

Rising incidence of pancreatic cancer

There is a rapid increase in the prevalence of cancer cases, and its growth is driven by factors such as an unhealthy diet, physical inactivity, tobacco and alcohol consumption, air pollution, and physical inactivity. The incidence of cancer cases rises dramatically due to the buildup of cancer cases specific to age and the less effective repair mechanisms that become less effective as the person grows older. Furthermore, there are a growing number of chronic infections that are thought to be risk factors for cancer cases, primarily in countries with low or middle incomes. Therefore, rising incidence is a significant factor propelling market demand.

Restraint:

High treatment costs

High treatment costs pose a significant threat to the pancreatic cancer market. Treatment for pancreatic cancer may be expensive and include radiation therapy, chemotherapy, surgery, and supportive care. Patients may find it difficult to afford or obtain treatment due to its high cost, which may negatively impact their capacity to get timely and effective care. However, the financial burden of treatment can deter patients from seeking necessary medical attention or opting for recommended treatment options. This can lead to delays in diagnosis, suboptimal treatment choices, and poorer treatment outcomes.

Opportunity:

Rise in clinical research

The increase in epidemiologic and basic clinical research is leading to improved prevention, diagnosis, and treatment. Researchers are continuously unravelling the complex molecular and genetic mechanisms underlying pancreatic cancer, paving the way for innovative treatment modalities. Moreover, the exploration of new drug targets, biomarkers, and personalized medicine strategies is a testament to the evolving landscape of pancreatic cancer research. Therefore, a rise in clinical research is a good opportunity for pancreatic cancer treatment.

Threat:

Side effects

Pancreatic cancer treatments have various side effects during and after the treatment, depending on the patient. The most common cancer treatment, chemotherapy, works to kill cancerous cells in the pancreas but also eliminates healthy cells from the body, which has a negative impact on health and the recurrence of side effects in patients. Additionally, there are certain adverse effects from radiation therapy used to treat cancer, like skin reddening, nausea, and appetite loss. In rare instances, even diarrhoea is caused by radiation exposure. Therefore, the side effects of pancreatic cancer treatment impede the growth of the market.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the pancreatic cancer market. The pandemic caused delays in cancer screenings, diagnoses, and treatment plans, among other routine healthcare services. Patients with pancreatic cancer faced hurdles in accessing timely medical care due to restrictions, reallocation of resources, and a shift in healthcare priorities toward managing the pandemic. Moreover, clinical trials and research activities were also affected, which slowed down the progress of new treatment modalities and therapeutic advancements.

The chemotherapy segment is expected to be the largest during the forecast period

The chemotherapy segment is estimated to hold the largest share. Chemotherapy is becoming increasingly common due to benefits like stopping cancer from spreading, killing cancer cells, slowing the growth of the disease, and using strong chemicals to kill rapidly growing cells. Moreover, chemotherapy is used in any stage of pancreatic cancer to kill the cancer cells, and the drugs are administered in cycles with an alternating period of diagnosis and recovery. Additionally, chemotherapy for pancreatic cancer can be given during surgery or in conjunction with radiation therapy.

The clinics segment is expected to have the highest CAGR during the forecast period

The clinics segment is anticipated to have lucrative growth during the forecast period. The primary drivers of the growth of specialty clinics or cancer centers are genuine treatment combined with high-quality services. The availability of clinical staff members is a benefit of specialty clinics because oncologists and medical professionals share the same entity and specialization, and the patient can easily and affordably receive a diagnosis and treatment. Specialty clinics only offer specialized types of medicine, such as cancer centers for cancer patients, making it easier to manage insurance, patient scheduling, and access to the most recent advancements in cancer treatment.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The region has a sizable and quickly expanding population, which raises the prevalence of pancreatic cancer cases. The prevalence of risk factors such as smoking, obesity, and diabetes further adds to the disease burden in this region. Furthermore, access to cancer treatment and the quality of healthcare infrastructure have both improved in the Asia-Pacific region. The availability of advanced diagnostic technologies, including imaging modalities and molecular testing, has enhanced the early detection and diagnosis of pancreatic cancer. This has led to improved patient outcomes and an increased demand for diagnostic services in this region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America has a high prevalence of pancreatic cancer, making it a crucial region for research, diagnosis, and treatment advancements. Considerable progress has been made in the understanding of the disease and the development of targeted therapies due to the region's strong research infrastructure and funding opportunities. Furthermore, North America has a well-established healthcare system that provides access to specialized healthcare services and advanced treatment options.

Key players in the market:

Some of the key players in the Pancreatic Cancer Market include Diffusion Pharmaceuticals, Novartis International AG, Amgen, Inc., Pharmacyte Biotech Inc., Polaris Pharmaceuticals, Inc., Clovis Oncology, OncoGenex Pharmaceuticals Inc., Oncolytics Biotech, Sun BioPharma, Inc., Eli Lilly and Company, Midatech Pharma PLC, F. Hoffmann-La Roche AG and Celgene Corporation.

Key Developments:

In Oct 2023, Sun Pharma and Zydus Life sciences announced that they have entered into a licensing agreement to co-market Desidustat, an oral treatment for anaemia associated with Chronic Kidney Disease (CKD) in India.

In Jan 2022, Novartis announced collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for Bio Medical Research, potentially leading to development of a treatment designed to promote the re growth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

Types Covered:

  • Pancreatic Neuroendocrine Tumors
  • Pancreatic Adenocarcinoma

Treatment Types Covered:

  • Immunotherapy
  • Surgery
  • Chemotherapy
  • Hormone Therapy
  • Targeted Drug Therapy
  • Radiation Therapy
  • Other Treatment Types

Diagnosis Covered:

  • Computerized Tomography (CT) Scans
  • Blood Test
  • Positron Emission Tomography (PET) Scans
  • Ultrasound
  • Magnetic Resonance Imaging (MRI)
  • Biopsy
  • Other Diagnosis

Stage of Cancers Covered:

  • Early Stage
  • Locally Advanced
  • Metastatic

Affected Areas Covered:

  • Endocrine
  • Exocrine

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Research Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pancreatic Cancer Market, By Type

  • 5.1 Introduction
  • 5.2 Pancreatic Neuroendocrine Tumors
  • 5.3 Pancreatic Adenocarcinoma

6 Global Pancreatic Cancer Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Immunotherapy
  • 6.3 Surgery
  • 6.4 Chemotherapy
  • 6.5 Hormone Therapy
  • 6.6 Targeted Drug Therapy
  • 6.7 Radiation Therapy
  • 6.8 Other Treatment Types

7 Global Pancreatic Cancer Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 Computerized Tomography (CT) Scans
  • 7.3 Blood Test
  • 7.4 Positron Emission Tomography (PET) Scans
  • 7.5 Ultrasound
  • 7.6 Magnetic Resonance Imaging (MRI)
  • 7.7 Biopsy
  • 7.8 Other Diagnosis

8 Global Pancreatic Cancer Market, By Stage of Cancer

  • 8.1 Introduction
  • 8.2 Early Stage
  • 8.3 Locally Advanced
  • 8.4 Metastatic

9 Global Pancreatic Cancer Market, By Affected Areas

  • 9.1 Introduction
  • 9.2 Endocrine
  • 9.3 Exocrine

10 Global Pancreatic Cancer Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Diagnostic Laboratories
  • 10.4 Research Laboratories
  • 10.5 Other End Users

11 Global Pancreatic Cancer Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Diffusion Pharmaceuticals
  • 13.2 Novartis International AG
  • 13.3 Amgen, Inc.
  • 13.4 Pharmacyte Biotech Inc.
  • 13.5 Polaris Pharmaceuticals, Inc.
  • 13.6 Clovis Oncology
  • 13.7 OncoGenex Pharmaceuticals Inc.
  • 13.8 Oncolytics Biotech
  • 13.9 Sun BioPharma, Inc.
  • 13.10 Eli Lilly and Company
  • 13.11 Midatech Pharma PLC
  • 13.12 F. Hoffmann-La Roche AG
  • 13.13 Celgene Corporation

List of Tables

  • Table 1 Global Pancreatic Cancer Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Pancreatic Cancer Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Pancreatic Cancer Market Outlook, By Pancreatic Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 4 Global Pancreatic Cancer Market Outlook, By Pancreatic Adenocarcinoma (2021-2030) ($MN)
  • Table 5 Global Pancreatic Cancer Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 6 Global Pancreatic Cancer Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 7 Global Pancreatic Cancer Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 8 Global Pancreatic Cancer Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 9 Global Pancreatic Cancer Market Outlook, By Hormone Therapy (2021-2030) ($MN)
  • Table 10 Global Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2021-2030) ($MN)
  • Table 11 Global Pancreatic Cancer Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 12 Global Pancreatic Cancer Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 13 Global Pancreatic Cancer Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 14 Global Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2021-2030) ($MN)
  • Table 15 Global Pancreatic Cancer Market Outlook, By Blood Test (2021-2030) ($MN)
  • Table 16 Global Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2021-2030) ($MN)
  • Table 17 Global Pancreatic Cancer Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 18 Global Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2021-2030) ($MN)
  • Table 19 Global Pancreatic Cancer Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 20 Global Pancreatic Cancer Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 21 Global Pancreatic Cancer Market Outlook, By Stage of Cancer (2021-2030) ($MN)
  • Table 22 Global Pancreatic Cancer Market Outlook, By Early Stage (2021-2030) ($MN)
  • Table 23 Global Pancreatic Cancer Market Outlook, By Locally Advanced (2021-2030) ($MN)
  • Table 24 Global Pancreatic Cancer Market Outlook, By Metastatic (2021-2030) ($MN)
  • Table 25 Global Pancreatic Cancer Market Outlook, By Affected Areas (2021-2030) ($MN)
  • Table 26 Global Pancreatic Cancer Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 27 Global Pancreatic Cancer Market Outlook, By Exocrine (2021-2030) ($MN)
  • Table 28 Global Pancreatic Cancer Market Outlook, By End User (2021-2030) ($MN)
  • Table 29 Global Pancreatic Cancer Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 30 Global Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 31 Global Pancreatic Cancer Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 32 Global Pancreatic Cancer Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.